VC
KURA icon

Vivo Capital’s Kura Oncology KURA Stock Holding History

Vivo Capital’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-525,262
Closed -$9.84M – 60
2021
Q3 		$9.84M Hold
525,262
– – 0.44% 38
2021
Q2 		$11M Hold
525,262
– – 0.47% 38
2021
Q1 		$14.8M Hold
525,262
– – 0.52% 37
2020
Q4 		$17.2M Sell
525,262
-524,738
-50% -$18.4M 0.77% 29
2020
Q3 		$32.2M Hold
1,050,000
– – 1.86% 13
2020
Q2 		$17.1M Buy
+1,050,000
New +$15.1M 1.23% 23

Other funds holding KURA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Vivo Capital's KURA Position: Q4 2021 in Review

Vivo Capital sold out of Kura Oncology (KURA) in Q4 2021, closing a stake of 525,262 shares — an estimated $9.84M sold.

Vivo Capital first reported a position in KURA in Q2 2020 and held it in 6 quarters. The position peaked at $32.2M in Q3 2020. 151 funds tracked by Wall St. Rank hold KURA as of Q4 2021.

  • Vivo Capital reported no remaining Kura Oncology position as of Q4 2021 after selling out during the quarter.
  • Vivo Capital sold 525,262 Kura Oncology shares in Q4 2021, an estimated $9.84M.
  • Vivo Capital first reported a position in Kura Oncology in Q2 2020 and held it in 6 quarters.
  • Vivo Capital's Kura Oncology position peaked at $32.2M in Q3 2020.
  • 151 funds tracked by Wall St. Rank held Kura Oncology as of Q4 2021.

Based on Vivo Capital's 13F filing for Q4 2021, filed 11 Feb 2022.